Please assess the completion status of the following clinical trial:

Trial Title: Interscalene Block With Low-dose IV vs. Perineural Dexamethasone for Shoulder Arthroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients having ambulatory arthroscopic shoulder surgery under ultrasound-guided interscalene block (rotator cuffs, acromioplasties, stabilizations, labral repairs, etc.)~* Age 18-70 years~Exclusion Criteria:~* Contraindication to interscalene block~* Known allergy/sensitivity to any study medications~* Having taken daily steroids for 10 days or longer anytime during the past year~* Body mass index \<18 or \>40~* History of uncontrolled nausea and vomiting with opioids or severe post-op nausea and vomiting (to prevent any need for higher doses of IV dexamethasone)~* Non-English speaking~* Revision procedures~* Additional procedures (e.g., removal of hardware, procedures involving other areas, etc.)~* Planned open procedures~* History of diabetes~* Arthroscopic irrigation and debridement secondary to infection~* Peripheral neuropathies affecting the operative extremity~* Having taken opiates daily for 10 days or longer immediately preceding surgery, 3 times a week for greater than 3 months anytime in the past year, or currently taking for anything other than shoulder pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Intravenous dexamethasone (Type: ACTIVE_COMPARATOR): Patients will receive 1 cc (1 mg) dexamethasone intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc saline.
- Perineural dexamethasone (Type: EXPERIMENTAL): Patients will receive 1 cc saline intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc (1 mg) dexamethasone.

Based on this trial design, predict the completion outcome and termination type (if applicable).